# Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy

> **NCT03702140** · PHASE2 · UNKNOWN · sponsor: **Shinshu University** · enrollment: 90 (estimated)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** "Teriparatide", "Forteo® or Teribon"

## Key facts

- **NCT ID:** NCT03702140
- **Lead sponsor:** Shinshu University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-09
- **Primary completion:** 2023-10-08
- **Final completion:** 2025-10-08
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2021-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03702140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03702140, "Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03702140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*